Welcome to our dedicated page for Collegium Pharmaceutical news (Ticker: COLL), a resource for investors and traders seeking the latest updates and insights on Collegium Pharmaceutical stock.
About Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc. (Nasdaq: COLL) is a leading specialty pharmaceutical company committed to improving the lives of patients living with chronic pain and other serious medical conditions. Headquartered in Stoughton, Massachusetts, the company leverages its proprietary DETERx® technology platform to develop and commercialize next-generation, abuse-deterrent medications. Collegium's innovative approach addresses the growing public health concerns surrounding the misuse and abuse of prescription drugs, particularly opioids, while maintaining efficacy for patients who require long-term pain management solutions.
Core Business and Product Portfolio
At the heart of Collegium’s operations is its portfolio of abuse-deterrent medications designed to mitigate risks associated with non-medical use. The company’s flagship product, Xtampza ER®, is an extended-release, oral formulation of oxycodone that employs DETERx® technology to maintain its safety and efficacy profile even when subjected to physical manipulation such as crushing or dissolving. Collegium also markets the Nucynta® franchise, which includes both immediate-release and extended-release formulations of tapentadol, used for managing acute and chronic pain.
In 2024, Collegium expanded its portfolio through the acquisition of Ironshore Therapeutics, adding Jornay PM®, a unique evening-dosed ADHD medication, to its offerings. This strategic move established the company’s presence in the growing neuropsychiatry market, diversifying its revenue streams and positioning it for long-term growth.
Technological Innovation: The DETERx® Platform
Collegium’s proprietary DETERx® technology is a cornerstone of its product development strategy. This platform enables the creation of extended-release formulations that are resistant to common forms of abuse, such as chewing, crushing, and dissolving. By integrating this technology into its medications, Collegium addresses two critical needs: providing effective pain relief for patients and reducing the potential for misuse and abuse. The DETERx® platform is protected by a robust portfolio of U.S. and international patents, underscoring Collegium’s commitment to innovation and intellectual property protection.
Strategic Growth and Market Position
Collegium has established itself as a key player in the specialty pharmaceutical industry through a combination of innovation, strategic acquisitions, and disciplined capital deployment. The company’s focus on responsible pain management has earned it a strong reputation among healthcare providers and patients alike. Its recent acquisition of Ironshore Therapeutics not only diversifies its product portfolio but also enhances its market presence in the neuropsychiatry segment.
With a strong financial foundation and a commitment to operational excellence, Collegium is well-positioned to navigate the challenges of a highly regulated industry. The company continues to invest in research and development, aiming to expand its portfolio and address unmet medical needs in both pain management and neuropsychiatry.
Commitment to Responsible Pain Management
Collegium is dedicated to advancing science-based solutions for pain management while prioritizing patient safety. The company actively engages with healthcare providers, policymakers, and the broader medical community to promote the responsible use of opioid medications. By combining innovative technology with a patient-centered approach, Collegium aims to set new standards in the treatment of chronic pain and other serious medical conditions.
Conclusion
Collegium Pharmaceutical Inc. exemplifies the integration of innovation, responsibility, and strategic growth in the pharmaceutical industry. Through its proprietary DETERx® technology, diverse product portfolio, and commitment to addressing critical public health challenges, the company continues to make meaningful contributions to the healthcare landscape. As it expands into new therapeutic areas like neuropsychiatry, Collegium remains focused on its mission to improve patient outcomes and create long-term value for stakeholders.
Collegium Pharmaceutical reported its 2020 financial results, marking its first full year of profitability, driven by Xtampza ER revenue growth and the acquisition of the Nucynta franchise. For the fourth quarter, net income reached $7.0 million compared to a $2.2 million loss in the same quarter of 2019. Xtampza ER generated $30.8 million in revenue, up 12% year-over-year, while Nucynta revenues fell 3% to $45.5 million. The company has reiterated its 2021 financial guidance, projecting Xtampza ER revenues between $155 million and $165 million.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced a conference call scheduled for February 25, 2021, at 4:30 p.m. Eastern Time. The call will cover the Company’s financial results and provide a corporate update.
To participate, call (877) 407-8037 (U.S.) or (201) 689-8037 (International), referencing the “Collegium Pharmaceutical Q4 2020 Earnings Call.” A replay will be available on the Company’s website shortly after the event.
Collegium Pharmaceutical (Nasdaq: COLL) announced its financial guidance for 2021, projecting Xtampza ER revenues between $155 million and $165 million and Nucynta franchise revenues between $175 million and $185 million. Adjusted EBITDA is expected between $160 million and $170 million, with total operating expenses projected between $125 million and $135 million. The company aims to leverage its cost structure and generate significant cash flow from operations while focusing on maximizing the potential of its pain management portfolio.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) reported strong Q3 2020 results, achieving record net income of $11.3 million and generating $34.2 million in cash flow from operations. Xtampza ER revenues rose 21% year-over-year to $32.1 million, while Nucynta revenues were $47.1 million. Operating expenses decreased by 12%, enhancing profitability, as reflected in an adjusted EBITDA of $41.8 million. Collegium secured exclusive formulary access for Xtampza ER with a national Medicare Part D plan, covering over 92 million lives, and settled patent litigation with Teva, allowing its generic launch in 2033.
Collegium Pharmaceutical announced the publication of a postmarketing analysis titled “Misuse, Abuse and Diversion of Xtampza ER,” featured in Pain Medicine. This study highlights that, despite a 50-fold increase in prescriptions for Xtampza ER following its launch, incidents of misuse, abuse, and diversion remained low. The analysis utilized RADARS® data to compare Xtampza ER to other opioid formulations. The company emphasized its commitment to ongoing studies and surveillance to contribute to the understanding of abuse-deterrent formulations.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) will host a conference call on November 5, 2020, at 4:30 p.m. ET. This call will focus on the Company's Q3 financial results and corporate updates. Investors can participate by dialing (877) 407-8037 or (201) 689-8037 for international access, and the audio webcast will be available on the Company's website. Recordings of the event will be retrievable shortly after its conclusion. Collegium aims to lead in responsible pain management with its headquarters in Stoughton, Massachusetts.
Collegium Pharmaceutical (Nasdaq: COLL) reached a settlement with Teva Pharmaceutical regarding patent litigation over the generic version of Xtampza ER. The agreement allows Teva to market its generic version starting September 2, 2033, pending FDA approval. The settlement confirms that Teva's proposed products infringe on Collegium's patents, which are valid and enforceable. Collegium's intellectual property portfolio includes 19 patents for Xtampza ER, valid through 2036, asserting the company's commitment to innovation in pain management.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) has appointed Dr. Rita Balice-Gordon to its Board of Directors, effective September 24, 2020. Dr. Balice-Gordon brings extensive scientific expertise, having served in senior roles at Muna Therapeutics and Sanofi, and as former Vice President at Pfizer. Collegium aims to enhance its leadership in responsible pain management through her insights. Management is optimistic about the contributions she will make during this significant phase in the company’s evolution.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced five poster presentations at the 14th Annual PAINWeek National Conference held virtually from September 11-13, 2020.
The posters focused on data related to abuse and misuse of its products, including Xtampza® ER and Nucynta® ER. The findings were aimed at reinforcing the company’s commitment to responsible pain management and addressing concerns about opioid abuse. Richard Malamut, M.D., emphasized the importance of sharing real-world evidence at this scientific forum.
Collegium Pharmaceutical (Nasdaq: COLL) announced five poster presentations at the virtual 14th Annual PAINWeek National Conference from September 11-13, 2020. These presentations focus on the company's pain management products, particularly Xtampza® ER, and explore topics such as its nonmedical use, online perceptions, diversion rates, and abuse potential compared to other opioids. The conference aims to highlight critical data regarding responsible pain management practices and the risks associated with opioid use. Important safety information regarding addiction and respiratory depression is also provided.
FAQ
What is the current stock price of Collegium Pharmaceutical (COLL)?
What is the market cap of Collegium Pharmaceutical (COLL)?
What does Collegium Pharmaceutical Inc. specialize in?
What is the DETERx® technology platform?
What are Collegium’s key products?
How does Collegium address opioid misuse and abuse?
What was the significance of the Ironshore Therapeutics acquisition?
Where is Collegium Pharmaceutical headquartered?
How does Collegium differentiate itself in the pharmaceutical industry?
What markets does Collegium operate in?
